Vectura’s COO set to step down

pharmafile | March 8, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing vectura 

Vectura’s Chief Operating Officer, Trevor Phillips, will step down from the board on 25 May before leaving the company on 31 May. According to Vectura, Phillips was a key figure in the acquisition of Activaero and its merger with Skyepharma in 2016. During the latter, he has also played a role in the integration between the companies.

Prior to working with Vectura, Phillips performed the role of COO and CEO of Critical Therapeutics – a company that was bought out by Cornerstone BioPharma in 2008, before its eventual takeover by Chiesi Farmaceutici. He had a role at GSK as CRM before this.

James Ward-Lilley, Chief Executive Officer, commented: “I would like to extend my personal thanks to Trevor for the support he has given me and for the highly professional way in which he has carried out his role in the business. Trevor has been with Vectura since 2010 and in that time he has been a significant driver of the transition of the Group into the business it is today. Having managed the initial integration of Skyepharma and Vectura, Trevor and I agreed that the AGM would be an appropriate time for him to transition out of the Company. The Board and I would like to thank Trevor for his contribution throughout his tenure, and we wish him well in his future endeavours.”

Related Content

Vectura removed from DDL Conference amid PMI deal

 Inhaler and medical device maker Vectura has been removed from pharma conferences Formulation and Delivery …


Vectura CEO to step down at end of June

Vectura is on course for a new leader to take up the company’s reins after …


Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled …

Latest content